[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overactive-bladder-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overactive-bladder-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,55,84,113,153,185,211,233,258,278,297,326,352,379,410],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100575251","phase-4-defining-the-safety-and-efficacy-of-posterior-tibial-nerve-stimulation-in-children-100575251",false,"NCT06769854","Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children","POSITRON-C","Inclusion Criteria:\n\n1. Age 5-21 years old (inclusive)\n2. Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization from the participant or the participant's parent\u002Flegal guardian\u002Flegally authorized representative (LAR)\n3. Minor participant is willing and able to provide assent (as applicable)\n4. History of primary or secondary non-neurogenic OAB as defined by a VDES score of ≥11 and a positive modified bother score within 30 days of consent\n5. Has previously tried and failed standard urotherapy and at least one anticholinergic or beta-3 adrenergic agonist\n6. Adequate fluid intake for age as reported by participant or parent\u002Flegal guardian\u002FLAR\n7. Micturition frequency of at least 8 times (mean)\u002Fday for at least 4 weeks prior to enrollment\n8. At least 1 daytime incontinence episode (mean)\u002Fday for at least 4 weeks prior to enrollment\n9. If on allowed treatment for OAB, stable dose for at least 30 days prior to screening and willingness to continue that dose for the duration of the study\n\nExclusion Criteria:\n\n1. Known or apparent untreated anatomical abnormality of the lower urinary tract (e.g., untreated ureterocele)\n2. Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)\n3. Presence of local skin lesions (e.g., rash, skin infections) on the medial surfaces of both ankles at the time of consent\n4. Metal implants in the medial ankle area\n5. Pacemakers or implantable defibrillators\n6. History of excessive bleeding\n7. Nerve damage that may impact the percutaneous tibial nerve or pelvic floor function\n8. History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)\n9. Known current, untreated UTI\n10. Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential\n11. Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety\n12. Previous treatment with this device or participation in this study or in any other study for the treatment of OAB\n13. High-grade vesicoureteral reflux (grades 4-5)\n14. Diagnosed diabetes insipidus (pituitary, nephrogenic, or acquired)\n15. Stage 4-5 chronic kidney disease (CKD) (since device may further disrupt or exacerbate abnormal urine flow)\n16. Significant post-void residual defined as \\>60 mL\n17. Initiation of or change of OAB treatment during screening or the duration of the study.",true,"ALL","5 Years","21 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The purpose of this study is to find out if overactive bladder (OAB) can be safely treated by stimulating a nerve near the ankle. This procedure is called percutaneous tibial nerve stimulation (PTNS). It will be done by a device called the Urgent PC. The Urgent PC works by sending weak electrical signals through a thin needle to the nerve near the ankle. Stimulating this nerve may change bladder control.",[28,29],"Overactive Bladder","Overactive Bladder Syndrome",[31,28,32,33,34,35,36,37,38,39,40,41,42],"PTNS","percutaneous tibial nerve stimulation","Urgent PC","urinary urgency","urinary incontinence","urinary frequency","OAB","urinary urge","Urinary Bladder","Urinary Bladder Diseases","Urologic Diseases","Pediatrics","NOT_YET_RECRUITING","2026-06-15",{"date":46,"type":47},"2026-06-17","ACTUAL",{"date":49,"type":22},"2027-04-01",{"date":51,"type":22},"2029-10-31",{"name":53,"class":54},"Chi Dang Hornik","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100506789","phase-2-examining-the-effects-of-intra-detrusor-botox-at-time-of-holep-in-men-with-overactive-bladder-symptoms-100506789","NCT05878951","Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms","A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms","Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Component of OAB symptoms including frequency, nocturia, urgency, and\u002For urge related incontinence\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to OnabotulinumtoxinA injections\n* Patients having a concurrent ureteroscopy +\u002F- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy\n* Patients who lack decisional capacity\n* Active urinary tract infection","MALE","18 Years","89 Years",{"count":66,"type":22},66,[68,69],"PHASE2","PHASE3","The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",[72,29,28,41],"Urinary Incontinence","RECRUITING","2026-06-02",{"date":76,"type":47},"2026-06-04",{"date":78,"type":47},"2023-07-13",{"date":80,"type":22},"2026-12-31",{"name":82,"class":54},"Northwestern University",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":83},"100542346","impact-of-ttns-on-bladder-symptoms-among-people-with-ms-a-rct-100542346","NCT06341673","Impact of TTNS on Bladder Symptoms Among People With MS, A RCT","Impact of Transcutaneous Tibial Nerve Stimulation on Bladder Storage Symptoms and Quality of Life in People With Multiple Sclerosis- A Randomised Controlled Trial\"","Inclusion Criteria:\n\n* Ambulatory (with or without assistive device)\n* Aged ≥18 years old\n* Able to understand spoken and written Arabic Language\n* Self-reported with at least one bladder storage symptom such as urinary frequency urinary urgency, nocturia, with or without urge urinary incontinence\n* Willing to give written informed consent\n* Able to understand how to complete the study outcome measures\n\nExclusion Criteria:\n\nPeople with MS will be excluded if they have one or more of the following criteria at randomization:\n\n* Indwelling urethral catheter\n* Indwelling suprapubic catheter\n* Bladder malignancy\n* Diabetic mellitus\n* Pregnant women or plan to be pregnant during the study intervention\n* Recent pelvic related surgery \\\u003C1 year\n* Pacemaker or other metallic internal devices\n* Urinary tract infections (UTIs) during recruitment phase\n* Unable to understand the instructions relating to operating the unit\n* Having a bladder BOTOX-injection in the last 12-month",{"count":92,"type":22},72,[94],"NA","Background: Neurogenic lower urinary tract dysfunction is common among people with multiple sclerosis (MS). Recent studies showed that bladder storage symptoms are predominant among MS with a pooled prevalence of frequency at 73.45% followed by urgency at 63.87%. Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive treatment to manage bladder storage symptoms; however, the effectiveness of TTNS is based on a small number of studies with the absence of high-quality evidence. This study aims to investigate the effectiveness of TTNS on bladder storage symptoms compared with sham TTNS among people with MS.Methods: The investigators will use a randomised sham controlled double blind study to explore the effectiveness of TTNS in the treatment of bladder storage symptoms in MS. the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) was followed to standardize the conduct and reporting of the current protocol. The recruitment plan is twofold: 1) Open recruitment for people with MS through King Fahd Hospital of the University communication channels; 2) people with any type of MS attending their routine appointments in MS clinic at King Fahd Hospital of the University, Al Khobar. The investigators will investigate the effectiveness of TTNS compared to sham TTNS on bladder storage symptoms and the effect on quality of life using ICIQ-OAB, ICIQ 3-day bladder diary, ICIQ-LUTS qol, and PSQI. Participant's perception of change post intervention will be evaluated using GPE. Outcomes will be measured at 0, 6 weeks and at 6 months post intervention. A sample size of 72 patients (36 in each group) is required to achieve 90% power with two-tailed tests at an alpha level of 0.05.\n\nConclusion: Multiple sclerosis is a long-term condition, and self-management is important. TTNS provide a safe, non-invasive intervention that can be administered at home. Should the trial determine that TTNS is effective compared to sham TTNS, the investigators will plan to integrate TTNS into standard clinical care pathways in MS.",[29],[98,99,100,101,102,103],"Multiple Sclerosis","Overactive bladder","Bladder storage symptoms","Incontinence","Tibial nerve stimulation","Stimulation","2026-05-13",{"date":106,"type":47},"2026-05-15",{"date":108,"type":47},"2024-03-15",{"date":110,"type":22},"2027-02-28",{"name":112,"class":54},"Hawra Al-Dandan",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100634858","real-world-experiences-and-voices-exploring-the-actual-lived-burden-of-oab-a-mixed-methods-multi-country-proms-study-on-oab-patients-quality-of-life-100634858","NCT07545148","Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life","REVEAL-OAB. Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life","REVEAL-OAB","Inclusion Criteria:\n\n* If they are over 18 years old.\n* They have been told by a doctor or other healthcare professional that they have symptoms that match OAB, or have been given a diagnosis of OAB.\n* They live in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, or the UK.\n* They have received the Patient Information Sheet from their health care provider, during an appointment, via email, or postal mail.\n* They can confirm they understand the Patient Information Sheet and that they want to take part in this study.\n\nExclusion Criteria:\n\n* They have not received information on this study from their own health care provider\n* They have a confirmed neurological condition known to affect bladder function (for example: multiple sclerosis, Parkinson's disease, spinal cord injury).\n* They have undergone major surgery directly involving the bladder, prostate, urethra, or pelvic structures that affect urinary function.\n* They presently have a urinary tract infection (UTI).\n* They have or have had cancer in their bladder, kidneys, prostate, or other urinary or reproductive organs",{"count":122,"type":22},2000,"OBSERVATIONAL","The main goal is to understand what it is truly like to live with OAB from the patient's perspective, including how it affects: daily activities, emotional wellbeing and mental health, social life and relationships, work and overall quality of life.",[126,29],"Overactive Bladder (OAB)",[128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143],"Real-world evidence;","Patient-centred research","Mixed-method study","International, multi-country study","Observational study","Overactive bladder (OAB) burden","Quality of life (QoL)","Emotional and psychosocial impact","Quantitative surveys","Patient-reported outcomes (PROs)","Qualitative interviews","Evidence to inform clinical practice and policy","Unmet needs in care","Real-life disease impact","Symptom impact and severity","Lived patient experience","2026-04-30",{"date":146,"type":47},"2026-05-06",{"date":148,"type":22},"2026-07-01",{"date":150,"type":22},"2027-02-01",{"name":152,"class":54},"European Association of Urology Research Foundation",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":161,"minAge":63,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100625002","phase-4-randomized-controlled-trial-comparing-low-dose-tadalafil-versus-solifenacin-for-management-of-overactive-bladder-in-women-multicenter-egyptian-national-study-100625002","NCT07416968","Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study","Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (WoMEN'S)","WoMEN'S","Inclusion Criteria:\n\n* OAB symptoms persisting for ≥3 months\n* OAB Symptom Score (OABSS) \\> 5 and urgency sub-score of OABSS ≥ 2\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Active urinary tract infection.\n* Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI\n* Pelvic organ prolapse stage ≥II according to POP-Q system.\n* History of pelvic radiation.\n* History of neurosurgical interventions.\n* Pregnancy or breastfeeding.\n* Neuropathic diseases affecting the lower urinary tract.\n* History of genitourinary malignancy.\n* Post-void residual urine (PVR) \\> 150 ml.\n* Vesical or lower ureteric stones.\n* Uncontrolled diabetes mellitus (HbA1c \\> 7).\n* Any psychological or psychiatric disorders.\n* Contraindications or allergy to the used medications.\n* History of surgeries in the urinary bladder.\n* History of pelvic surgeries within 6 months.\n* Voiding dysfunctions.","FEMALE","75 Years",{"count":164,"type":22},480,[25],"Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage.\n\nWomen who join the study will be randomly placed into one of two groups:\n\nOne group will take tadalafil (5 mg), a medicine taken once a day.\n\nThe other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day.\n\nThe study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits.\n\nThe main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects.\n\nWomen aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.",[126,29],[28,37,169,170,171,172,173,174],"Tadalafil","Solifenacin","Low dose tadalafil","Urgency","frequency","Urge Urinary Incontinence","2026-02-17",{"date":177,"type":47},"2026-02-18",{"date":179,"type":47},"2025-09-01",{"date":181,"type":22},"2026-12",{"name":183,"class":54},"Mansoura University",14,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":191,"maxAge":63,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":209,"locationsCount":83},"100508026","yoga-for-treatment-of-overactive-bladder-in-pediatric-patients-100508026","NCT05895045","Yoga for Treatment of Overactive Bladder in Pediatric Patients","Inclusion Criteria:\n\n* 8-18 years of age\n* History of non-neurogenic overactive bladder or detrusor overactivity and\u002For urinary incontinence (ICD 10 codes respectively - N32.81, N39.498)\n* Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent\u002Flegal guardian\n* Minor participant is willing and able to provide assent (as applicable)\n* Vancouver Dysfunctional Elimination Syndrome\\[15\\] score of ≥11 and a positive modified bother score within 30 days of consent\n\nExclusion Criteria:\n\n* Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele)\n* Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)\n* Nerve damage that may impact pelvic floor function\n* History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)\n* Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable)\n* Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential\n* Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety","8 Years",{"count":193,"type":22},40,[94],"The goal of this pilot study is to assess the impact of yoga as a treatment modality in pediatric patients age 8-18 diagnosed with idiopathic overactive bladder as measured by validated questionnaires and urinary biomarkers. The main question it aims to answer is: Does yoga help improve overactive bladder symptoms in this patient population? Participants will take part in a weekly yoga session for a total of 6 weeks with validated questionnaires and urinary samples for biomarkers to be completed at the beginning, middle and end of the study. This study will follow a cross-over study design and patients will receive standard of care while not in the active treatment arm.",[28,29,197],"Overactive Detrusor",[199,200,201,202],"bladder","overactive","detrusor","pediatric","2026-01-29",{"date":205,"type":47},"2026-01-30",{"date":207,"type":47},"2026-01-01",{"date":80,"type":22},{"name":210,"class":54},"Duke University",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":217,"maxAge":191,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":231,"locationsCount":83},"100358840","phase-3-oxybutynin-for-post-surgical-bladder-pain-and-urgency-100358840","NCT03952299","Oxybutynin for Post-surgical Bladder Pain and Urgency","Inclusion Criteria:\n\n* Patients who will undergo bladder surgery that requires an indwelling bladder catheter after surgery.\n* Age Range: Four to 8 years of age are eligible for the study.\n\nExclusion Criteria:\n\n* Patients who have had prior bladder surgery.\n* Patients who have neurologic disease that could impair bladder sensation.\n* Patients who are already taking antimuscarinic or antispasmodic medications.\n* Patients with glaucoma, any neurologic disease, dementia, impaired mentation or disorder of the central nervous system.\n* Patients taking any medication that affects the central nervous system such as antidepressant, anxiolytic or antipsychotic medications.\n* Less than four years of age cannot have the transdermal patch due to fixed dose. Over 8 years of age: less than 5% of our patients, who undergo this surgery, are over 8 years of age and is usually a rare adolescent. Data in an older cohort may confuse the results since they respond differently to bladder surgery due to larger incision and longer hospital stay with a catheter.","4 Years",{"count":219,"type":22},100,[69],"Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.",[29,223],"Neuropathic Bladder",[225],"Transdermal Oxybutynin","2026-01-28",{"date":203,"type":47},{"date":229,"type":47},"2021-09-01",{"date":80,"type":22},{"name":232,"class":54},"University of California, Davis",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":83},"100429512","btl-emsella-chair-versus-sham-for-the-treatment-of-overactive-bladder-100429512","NCT04873037","BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder","A Single-Blind, Randomized Study of the BTL EmsellaTM Chair Versus Sham for the Treatment of Overactive Bladder","EmsellaOAB","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about AEs and other clinically important information.\n2. Women and men ≥ 18 years of age\n3. Self-reported bladder symptoms present ≥ 3 months\n4. Self-reported failed conservative care of behavioral modifications and\u002For oral medications\n5. On a stable dose of antimuscarinics\u002Fbeta-3 agonists for ≥ 4 weeks, and willing to remain on the medication for the duration of the study OR discontinued antimuscarinics\u002Fbeta-3 agonists for ≥ 2 weeks\n6. Ambulatory and able to use a toilet independently, without difficulty\n7. Subject agrees not to start any new treatment for OAB (medication or otherwise) during the treatment and follow-up periods.\n\n   For Females Only:\n8. If of child-bearing age and female, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, IUD, implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, buttocks, and thighs, at the discretion of the investigator.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, copper intrauterine devices, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n7. Active urethral diverticula\n8. Known vesicoureteral reflux\n9. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n10. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation. Skin cancers are permitted.\n11. Subject has used the BTL EMSELLA device previously\n12. Subject has urinary incontinence of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n13. Current urinary tract infection. If a subject has a confirmed symptomatic UTI at screening, per investigator's clinical judgment, they will be deferred from screening until treatment is completed, and may resume once symptoms have resolved\n14. Current use of neuromodulation therapy, including interstim and PTNS, for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    For Females Only:\n17. Pregnant, or planning to become pregnant, at screening or anytime throughout the study period\n\n    * Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.",{"count":242,"type":22},166,[94],"The purpose of this clinical trial is to compare the Emsella Chair therapy to Sham and to determine whether electromagnetic technology is effective in the treatment of overactive bladder (OAB). Currently there are no other studies utilizing the Emsella Chair for the treatment of OAB. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.",[29,28,246,247],"Urinary Frequency","Urinary Urgency",[28],"2025-12-05",{"date":251,"type":47},"2025-12-11",{"date":253,"type":47},"2021-11-22",{"date":255,"type":22},"2028-12",{"name":257,"class":54},"Corewell Health East",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":16,"sex":161,"minAge":63,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":83},"100523350","improving-overactive-bladder-treatment-access-and-adherence-100523350","NCT06094543","Improving Overactive Bladder Treatment Access and Adherence","Improving Overactive Bladder Treatment Access and Adherence Through Personalized Behavioral Modifications and Mobile Technology-Based Interventions","Inclusion Criteria:\n\n* Female aged 18 years or older\n* OAB symptoms for at least 3 months\n* English\u002FSpanish language skills and cognitive status sufficient to complete all study related materials\n* Behavioral treatment naïve patients\n* Previously treated OAB patients without supervised pelvic floor physical therapy or pharmacotherapy within 1 year\n\nExclusion Criteria:\n\n* Post void residual urine \\> 150ml\n* Confirmed diagnosis of Interstitial Cystitis\u002FPainful Bladder Syndrome (IC\u002FPBS)\n* Pregnant or breastfeeding patients\n* Patients residing in a nursing home\n* Comorbid neurological conditions, including spinal cord injury, progressive neurologic illnesses (e.g. Multiple Sclerosis, Parkinson's disease) or central nervous system disease (e.g. brain tumor, stroke)\n* Stage 2 or greater pelvic organ prolapse\n* Any history of urethral stricture\n* Any history of pelvic irradiation\n* Any history of bladder malignancy\n* Current symptomatic urinary tract infection (UTI), unresolved by the time of enrollment\n* Hematuria without a clinical evaluation\n* History or current use of indwelling urinary foley catheterization, suprapubic tube or intermittent catheterization\n* Patients with UI treated with onabotulinumtoxinA, sacral neuromodulation, or percutaneous tibial nerve stimulation (third line therapies)",{"count":266,"type":22},30,[94],"Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and embarrassing conditions that affect 33 million Americans. Yet, both are underdiagnosed and undertreated with significant financial and health-related consequences. OAB syndrome is characterized by urinary urgency, with and without urinary incontinence, urinary frequency, and nocturia. Evidence-based treatments are available, including behavioral therapy, pharmacotherapy, and minimally invasive procedures. Diagnosis and treatment are also associated with improvement in urinary symptoms and overall quality of life (QOL).3 However, 70-80% of treated patients will discontinue use of therapy in the first year due to one of several factors (e.g., cost, tolerability, inadequate effect). In addition, only 4.7% progress to advanced therapies suggesting undertreatment for those that need it most. Vulnerable populations are especially at risk, as therapy utilization are lowest among older, lower income, and\u002For minority groups. Poor access, insufficient patient education regarding disease chronicity, expected outcomes, costs, and potential side effects lead to unrealistic patient perceptions about therapy. This leads to suboptimal therapy duration, poor treatment efficacy, adherence, and undertreatment. The study aims to evaluate a tailored patient-centered tool to begin the treatment process.",[29,72],"2025-11-25",{"date":272,"type":47},"2025-11-26",{"date":274,"type":47},"2024-11-01",{"date":181,"type":22},{"name":277,"class":54},"Stanford University",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":161,"minAge":63,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":83},"100558059","oral-lactobacillus-supplementation-as-treatment-for-overactive-bladder-syndrome-a-randomised-controlled-trial-100558059","NCT06546189","Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial","Inclusion Criteria:\n\n* diagnosis of overactive bladder syndrome or mixed urinary incontinence with predominance of overactive bladder symptoms\n\nExclusion Criteria:\n\n* under age 18\n* neurogenic overactive bladder",{"count":219,"type":22},[94],"Background: Overactive bladder describes a syndrome characterized by frequent urges to urinate and increased urination with or without nocturia and with or without urinary incontinence. Overactive bladder affects approximately 13% of older women and thus represents a condition with high prevalence. Affected women report significant limitations in daily life, as well as social isolation. Despite the high occurrence of this condition, therapeutic options are limited, partly because the etiology of this condition is not fully understood. Increasingly, studies suggest an imbalance in the urogenital microbiome as a possible cause of the development of the condition. Therefore, the aim of this study is to test, whether the oral administration of a lactobacillus preparation can lead to a reduction in symptoms.\n\nDesign: Randomized controlled study\n\nMethods: Intake of OMNi BiOTiC® 41167 or placebo twice daily for 6 months; swabs (vaginal and urethral) and urine samples from a single-use catheter for microbiome determination at 0, 3, and 7 months.\n\nOutcome: Reduction of subjective symptoms (yes\u002Fno) after 3 and 7 months; reduction of Overactive Bladder Symptom Score after 3 and 7 months; change in the urogenital microbiome after 3 and 7 months (comparison of intervention vs. placebo).",[29],"2025-09-23",{"date":290,"type":47},"2025-09-29",{"date":292,"type":47},"2025-04-01",{"date":294,"type":22},"2027-10-01",{"name":296,"class":54},"Medical University of Vienna",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":83},"100607111","platelet-rich-plasma-versus-botulinum-toxin-for-refractory-overactive-bladder-a-randomized-trial-100607111","NCT07184307","Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial","Intra-vesical Injection of Platelet-Rich Plasma Compared With Botox for Management of Patients With Refractory Overactive Bladder: A Comparative Randomized Study","Inclusion Criteria:\n\n* Age 18 years or older\n* History of urgency, frequency, nocturia, with or without urge urinary incontinence, lasting for at least 6 months\n* Failure of standard medical treatment (antimuscarinics, beta-3 adrenergic agonists, or other appropriate therapy) for at least 6 months\n* Willing and able to complete bladder diaries, questionnaires, and urodynamic testing\n* Provides informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Previous intravesical biological therapy (e.g., platelet-rich plasma or botulinum toxin)\n* Prior pelvic or bladder surgery that may affect bladder function\n* Active urinary tract infection or sexually transmitted infection\n* Vaginitis or chronic bacterial prostatitis\n* Bladder or lower ureteral stones confirmed by imaging\n* Bladder outlet obstruction on urodynamic study\n* Bladder malignancy (mass on imaging or malignant cells on cytology)\n* Use of indwelling urinary catheter\n* Severe uncontrolled medical conditions (e.g., uncontrolled diabetes, advanced renal or hepatic impairment)\n* Known hypersensitivity to botulinum toxin or contraindication to platelet-rich plasma preparation (e.g., coagulopathy, inability to discontinue anticoagulation safely)",{"count":305,"type":22},48,[94],"Overactive bladder is a common condition that causes sudden urges to urinate, frequent urination, night-time urination, and sometimes leakage of urine. Many people with overactive bladder improve with lifestyle changes and medicines. However, some patients do not respond to these standard treatments and continue to suffer from bothersome symptoms. This study is designed to help patients who have not improved with available medical therapy.\n\nTwo treatments will be compared in this research. The first treatment uses platelet-rich plasma. Platelet-rich plasma is made from a patient's own blood and contains growth factors that may help repair the lining of the bladder and improve bladder function. The second treatment uses botulinum toxin. Botulinum toxin is a protein that can reduce unwanted bladder contractions and is already approved for use in patients with overactive bladder who did not respond to other treatments.\n\nThe purpose of this study is to evaluate whether platelet-rich plasma injection into the bladder wall is safe, effective, and durable when compared with botulinum toxin injection into the bladder muscle. We believe that platelet-rich plasma may improve bladder health by encouraging tissue repair and reducing inflammation, while botulinum toxin may reduce bladder overactivity by blocking chemical signals that cause muscle contractions.\n\nThis study will take place at Benha University Hospital in Egypt. About 48 adult participants with overactive bladder that has not improved after at least six months of medical therapy will be enrolled. Participants will be randomly assigned to one of two groups. One group will receive platelet-rich plasma injections into the bladder lining, and the other group will receive botulinum toxin injections into the bladder muscle. The procedures will be performed under anesthesia using a cystoscope, which is a thin instrument inserted into the bladder.\n\nParticipants will be followed for one year. At several time points during follow-up, they will complete bladder symptom questionnaires, keep a voiding diary, and undergo urodynamic studies to measure bladder capacity and function. Researchers will also monitor safety by recording any side effects, such as urinary tract infections or temporary difficulty emptying the bladder.\n\nThe main goal of this study is to determine whether platelet-rich plasma can reduce symptoms of overactive bladder as effectively as botulinum toxin, with fewer side effects and longer-lasting results. If successful, platelet-rich plasma could offer a new treatment option for patients who continue to struggle with overactive bladder despite standard medical therapy.",[29,309,310],"Urinary Urge Incontinence","Detrusor Overactivity",[312,313,28,314,247,246,174,310,315,316],"Platelet-Rich Plasma","Botulinum Toxin Type A","Refractory Overactive Bladder","Intravesical Injection","Regenerative Therapy","2025-09-13",{"date":319,"type":47},"2025-09-19",{"date":321,"type":47},"2025-04-15",{"date":323,"type":22},"2026-04-15",{"name":325,"class":54},"Benha University",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":161,"minAge":63,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":83},"100599201","home-based-transcutaneous-remotely-monitored-posterior-tibial-neuromodulation-100599201","NCT07081412","Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation","Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation System in Overactive Bladder: A Randomized Controlled Trial","TRIP-HOME","Inclusion Criteria:\n\n1. Patients who are ≥18 years old and female patients diagnosed with OAB\\* in Urology or Urogynecology outpatient clinics and who meet the inclusion criteria\n2. Being able to continue their T-PTNS\\*\\* treatment at home with the mobile application and accepting this,\n3. Having a smartphone compatible with the application for T-PTNS and being able to use the application\n4. Agreeing to be followed up for one year after treatment,\n5. Having stopped all antimuscarinics for at least two weeks,\n6. Being able to stand and use the toilet independently without difficulty,\n7. Volunteers who are willing to participate, have been informed about the study and have given signed informed consent, stating that they can comply with the requirements and restrictions listed in the informed consent form (ICP) and this protocol.\n\nExclusion Criteria:\n\n1. Patients under the age of 18\n2. Patients who are pregnant according to the results of a pregnancy test with urine or blood test, or who are planning a pregnancy during the study period, or who are breastfeeding\n3. Patients diagnosed with neurogenic bladder\n4. Patients with Dabetes Mellitus whose blood sugar cannot be controlled\n5. Patients with a history of allergic reactions on the skin\n6. Cases with prolapse greater than Stage-2 according to the POP-Q staging system and extending beyond the hymen\n7. Cases with a PVR evaluation of 100 ml and above with USG\n8. Contraindications for T-PTNS treatment (patients with pacemakers, implantable defibrillators or metal prostheses\n9. Patients with urinary tract infection\\*\n10. Having had botox applied to the bladder or pelvic floor muscles within the last year\n11. Having had a previous surgery related to the pelvic floor\n12. Current TENS use in the pelvic region, back or legs\n13. Having received PTNS treatment before\n14. Use of Interstim or Bion\n15. Those who do not accept the treatment or follow-up to be performed\n16. Those who may have problems complying with the requirements of the study plan\n17. Negative benefit\u002Frisk ratio determined by the investigator\n18. Those who have been included in any other clinical trial or use of investigational drug\u002Fdevice therapy within 30 days before the study visit",{"count":21,"type":22},[94],"To record the T-PTNS device (SmartUric) treatment performed by the patient at home via a mobile application in a remotely monitorable, secure and interactive manner with registration notes and a sham control group.",[29,126,338],"Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)",[340,341,342,343],"overactive bladder","neuromodulation","Posterior Tibial Nerve Stimulation","Quality of Life","2025-07-22",{"date":346,"type":47},"2025-07-23",{"date":348,"type":47},"2025-06-24",{"date":80,"type":22},{"name":351,"class":54},"Ege University",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":161,"minAge":63,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":83},"100569541","phase-4-optimal-intravesical-lidocaine-volume-for-pain-relief-during-office-intra-detrusor-onabotulinum-toxin-a-injections-100569541","NCT06695585","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections: a Prospective Randomized Superiority Trial","Inclusion Criteria:\n\n* Adult female, \\>18 years, English-speaking (surveys utilized are not validated in all languages)\n* Able to provide informed consent\n* Indications: Refractory urge urinary incontinence, Refractory urinary urgency and frequency, Neurogenic bladder (without sensory deficit)\n\nExclusion Criteria:\n\n* Untreated urinary tract infection at the time of procedure\n* Contra-indication to Botox\n* Contraindication to intravesical lidocaine\n* Inability to provide informed consent\n* Pregnancy, breast-feeding, intending to become pregnant within 6 months of treatment",{"count":360,"type":22},36,[25],"The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.",[28,29,247,246,364,365],"Urge Incontinence","Neurogenic Bladder",[367,368,369],"Bladder Botox","Intravesical lidocaine","office Botox","2024-11-15",{"date":372,"type":47},"2024-11-19",{"date":374,"type":22},"2024-12-01",{"date":376,"type":22},"2025-12-01",{"name":378,"class":54},"University of Louisville",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":161,"minAge":386,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":395,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100563554","transcutaneous-tibial-nerve-stimulation-for-overactive-bladder-syndrome-and-associated-gait-changes-in-post-menopausal-women-100563554","NCT06617676","Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome and Associated Gait Changes in Post-menopausal Women","TTNS","Inclusion Criteria: Inclusion criteria include females over 60 years of age who score an 8 or greater on the OAB-V8 with no exclusion criteria.\n\n\\-\n\nExclusion Criteria: those who experience stress UI only, have a pacemaker, neurologic deficit (e.g. Parkinson\\'s disease, multiple sclerosis, spinal cord injury), current urinary tract infection, known active cancer, or current OAB medication use (Tolterdine, etc.) with consideration of a washout period, and inability to walk 30 meters.\n\n\\-","60 Years","85 Years",{"count":389,"type":22},60,[94],"The goal of this clinical trial is to learn if surface tibial electrical stimulation (mild electrical signals on the inside of the ankle) helps women 60 years or older with urine leakage that happens on the way to the bathroom or at night time. The main questions it aims to answer are: 1). How many treatments per week over a 12-week period improve a person\\'s bladder symptoms?; 2). Is a person more confident that they will not fall and \u002F or leak urine on the way to the bathroom after the treatment with the electrical stimulation treatments; 3). Does the way a person walks when they need to go to the bathroom change after they have had the electrical stimulation? They will visit the clinic 3 times to complete several questionnaires and walk with a full bladder and empty bladder. On the first visit, the participant will be taught how to use the electrical stimulation device. Participants will either receive the treatment 2 or 4 times per week for 12 weeks or no treatment with the option to receive treatment following the 12 weeks. Participants will be given a bladder diary to complete at the start of treatment, at 6 weeks, then at 12 weeks and will be instructed in completion. They will drink water until they have a strong urge to urinate, then will walk along an electronic pathway and will go empty their bladder. After emptying, they will walk back along the electronic pathway again. They will also complete a Timed Up and Go test - stand up from a chair, walk 3 meters, then turn around, walk back, then sit down. At the 6th week follow up and the 12th week follow up, they will complete each questionnaire again and complete the walking tasks again.",[29,393,394],"Urinary Incontinence, Urge","Nocturia",[396,397,398,399,400,394],"Overactive bladder syndrome","Transcutaneous sacral nerve stimulation","Falls","Urinary urgency","Urinary frequency","2024-09-26",{"date":403,"type":47},"2024-09-27",{"date":405,"type":22},"2024-10",{"date":407,"type":22},"2026-03",{"name":409,"class":54},"Louisiana State University Health Sciences Center Shreveport",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":16,"sex":161,"minAge":63,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":83},"100456240","phase-4-vaginal-estradiol-vs-oral-beta-3-agonist-for-overactive-bladder-syndrome-100456240","NCT05221021","Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome","Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Raw score of 14 or more on OAB-q SF (adjusted score of 20)\n* Postmenopausal defined by not having a period for 12 months or bilateral oophorectomy a least 12 months status post procedure, or women with prior hysterectomy and preserved ovaries over age 55 years old or having a documented follicle stimulating hormone level greater than 40mIU\u002FmL.\n* Ability to speak and read English\n\nExclusion Criteria:\n\n* Contraindications to Vaginal Estrogen or Mirabegron\n* Post void residual \\>200mL or \\>1\u002F3 patient's total bladder volume\n* Currently on or previously taking anticholinergic or beta- 3 agonists within the past 1 month\n* Symptomatic pelvic organ prolapse greater than Stage 2, contraindication to vaginal estrogen therapy\n* Undiagnosed postmenopausal vaginal bleeding within the past 12 months\n* Current diagnosis of Multiple sclerosis, Parkinson's Disease, prior spinal cord injury, Spina Bifida, prior pelvic irradiation, Interstitial Cystitis, recurrent urinary tract infection.",{"count":418,"type":22},152,[25],"A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.",[29],"2024-08-15",{"date":424,"type":47},"2024-08-19",{"date":426,"type":47},"2022-10-01",{"date":428,"type":22},"2027-01-30",{"name":430,"class":431},"Walter Reed National Military Medical Center","FED"]